Biblio Discovery — Demo Discovery Service

10 hasil untuk "Gabriel Funingana"

Menampilkan 1–10 · 0,82 detik · RSS

  1. Artikel Jurnal

    A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study

    Tristan Barrett; Simon Pacey; Kelly Leonard dkk.

    European Urology Open Science, Vol. 38 · 2022 · Inggris · DOAJ Scopus

    Background: Active surveillance (AS) is a preferred management option for men with prostate cancer with favourable prognosis. However, nearly half of men on AS switch to treatment within 5 years, so therapeutic strategies to prevent or delay disease progression could be considered. The androgen…

  2. Artikel Jurnal

    Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review

    Ying-Wen Wang; Isaac Allen; Gabriel Funingana dkk.

    BJC Reports, Vol. 3 No. 1 · 2025 · Inggris · DOAJ

    Abstract Background PARP inhibitors are effective in treating ovarian cancer, especially for BRCA1/2 pathogenic variant carriers and those with HRD (homologous recombination deficiency). Concerns over toxicity and costs have led to the search for predictive biomarkers. We present an updated…

  3. Artikel Jurnal

    Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients

    Maria Delgado-Ortet; Vlad Bura; Ionut-Gabriel Funingana dkk.

    Frontiers in Oncology, Vol. 15 · 2025 · Inggris · DOAJ Scopus

    BackgroundHigh-grade serous carcinoma is a highly metastatic disease with a limited longterm disease control from systemic anti-cancer treatment, for which the radiological treatment response assessment metrics are imprecise. In this work, we developed noninvasive imagingbased measurements of…

  4. Artikel Jurnal

    Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models

    Jacob S. Bedia; Antonio Delgado-Gonzalez; Ying-Wen Huang dkk.

    Cell Reports Medicine, Vol. 6 No. 9 · 2025 · Inggris · DOAJ Scopus

    Summary: Tubo-ovarian high-grade serous carcinoma (HGSC), the most lethal gynecologic malignancy, initially responds to platinum-based chemotherapy, but due to frequent defects in the DNA damage response (DDR), most tumors develop resistance. The molecular mechanisms underlying clinical platinum…

  5. Artikel Jurnal

    Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

    Leonardo Rundo; Lucian Beer; Lorena Escudero Sanchez dkk.

    Frontiers in Oncology, Vol. 12 · 2022 · Inggris · DOAJ Scopus

    BackgroundPathological response to neoadjuvant treatment for patients with high-grade serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS) for omental tumor deposits. The main limitation of CRS is that it requires surgical sampling after initial neoadjuvant…

  6. Artikel Jurnal

    The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma

    Philip Smith; Thomas Bradley; Lena Morrill Gavarró dkk.

    Nature Communications, Vol. 14 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a cohort of 276 women with relapsed ovarian high grade serous carcinoma in the BriTROC-1 study. Panel sequencing…

  7. Artikel Jurnal

    Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

    James Spicer; Bristi Basu; Ana Montes dkk.

    Nature Communications, Vol. 14 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring…

  8. Artikel Jurnal

    Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-13C MRI

    Lucian Beer; Vlad Bura; Stephan Ursprung dkk.

    EJNMMI Research, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background To evaluate the capability of hyperpolarized [1-13C] pyruvate MRI to predict pathologic response to neoadjuvant treatment in multi-site abdominopelvic disease of high-grade serous ovarian cancer (HGSOC) patients and to compare 13C MRI and [18F]-FDG PET/CT measurements for…